Insmed Incorporated (NASDAQ:INSM) Given Average Recommendation of “Buy” by Brokerages

Shares of Insmed Incorporated (NASDAQ:INSM) have been given an average rating of “Buy” by the sixteen analysts that are presently covering the company, Marketbeat reports. Sixteen equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $82.73.

A number of research analysts have recently weighed in on the company. StockNews.com lowered Insmed from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. Bank of America raised their price objective on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Morgan Stanley raised their price objective on Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a research report on Friday, July 12th. Stifel Nicolaus increased their price target on shares of Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, UBS Group increased their price target on shares of Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a report on Friday, August 9th.

Insmed Trading Down 2.4 %

Shares of INSM stock opened at $71.94 on Thursday. Insmed has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The firm has a market capitalization of $10.69 billion, a PE ratio of -13.76 and a beta of 1.11. The stock has a fifty day simple moving average of $73.98 and a two-hundred day simple moving average of $59.42.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The business had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. During the same period in the previous year, the firm earned ($1.78) EPS. The business’s quarterly revenue was up 17.0% compared to the same quarter last year. On average, analysts predict that Insmed will post -5.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares in the company, valued at approximately $7,951,559.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of Insmed stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,882 shares of company stock valued at $5,765,446. 4.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC acquired a new position in shares of Insmed in the third quarter worth about $30,000. EntryPoint Capital LLC acquired a new position in shares of Insmed in the first quarter worth about $33,000. Fidelis Capital Partners LLC acquired a new position in shares of Insmed in the first quarter worth about $34,000. GAMMA Investing LLC raised its position in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares during the period. Finally, First Horizon Advisors Inc. raised its position in shares of Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.